the main research aim of this Network for Optimized Astatine labeled Radiopharmaceuticals (NOAR) COST Action is to successfully demonstrate that one of the most promising radionuclides for Targeted Alpha Therapy (TAT), namely Astatine-211, can become the European standard for treatment of certain cancerous pathologies.
Network for Optimized Astatine labele
Chelatec will be soon attending the first open COST NOAR meeting that will be fully dedicated to the Alpha-Emitter Astatine-211.